C4 Therapeutics Partners with Pfizer for Clinical Trial

The latest announcement is out from C4 Therapeutics ( (CCCC) ).

On October 1, 2025, C4 Therapeutics announced a clinical trial collaboration and supply agreement with Pfizer. Under this agreement, Pfizer will provide elranatamab, a BCMAxCD3 bispecific antibody, at no cost for C4T’s upcoming Phase 1b trial. This trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab for treating relapsed/refractory multiple myeloma. The collaboration aims to establish an optimal dose for this combination therapy, potentially improving outcomes for multiple myeloma patients.

The most recent analyst rating on (CCCC) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on C4 Therapeutics stock, see the CCCC Stock Forecast page.

Spark’s Take on CCCC Stock

According to Spark, TipRanks’ AI Analyst, CCCC is a Neutral.

C4 Therapeutics’ overall stock score is primarily impacted by its weak financial performance and valuation. The company’s ongoing losses and negative cash flows are significant concerns, while technical indicators suggest bearish trends. The lack of earnings call data and corporate events further limits positive factors influencing the score.

To see Spark’s full report on CCCC stock, click here.

More about C4 Therapeutics

C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop new medicines that transform patients’ lives. The company is progressing targeted oncology programs through clinical studies and utilizes its TORPEDO® platform to design and optimize small-molecule medicines aimed at difficult-to-treat diseases.

Average Trading Volume: 1,659,382

Technical Sentiment Signal: Sell

Current Market Cap: $158.7M

For an in-depth examination of CCCC stock, go to TipRanks’ Overview page.